⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 22, 2026PLoS ONEOpen Access

Correction: Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells

Alexandra Calescibetta Robert Dalton Nicole Fortenbery Grace Ward Sean Christiansen Xianghong Chen Pingyan Cheng Tiffany Razabdouski Annelise J. Glode Nhan Tu Thu Le Trinh Jinghong Liu Kenneth L. Wright Wei Sheng Erika A. Eksioglu

View Full Paper

Ask AI

Bookmark

Share

Key Points

The primary aim is to investigate the effects of combining lenalidomide with cytokines on NK cell activity.
Examined the expression levels of activating receptors and perforin/granzyme in NK cells.
Utilized in vitro assays to assess the impact of the combination treatment on NK cell function.
Lenalidomide significantly increased activating receptor expression on NK cells compared to control.
Combined treatment showed enhanced perforin and granzyme expression in NK cells.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Shows enhanced NK cell activation through lenalidomide and cytokine combination, highlighting potential immunotherapy benefits.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Calescibetta et al. (2026) studied this question.

synapsesocial.com/papers/69ec598788ba6daa22dab623 https://doi.org/10.1371/journal.pone.0348020

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cellsOriginal Research · 2026 · 1 citations
2IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II StudyEarly-Phase Clinical Trial · 2011 · 90 citations
3NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockadeOriginal Research · 2015 · 65 citations
4Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression2024 · 18 citations
5Abstract 7756: A tumor-targeting IL-12 immunocytokine therapy increases peripheral natural killer (NK) cells with phenotypes associated with increased tumor cell lysis in patients with advanced solid tumorsClinical Trial · 2026

More related papers

Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies2021
Supplementary Figure S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity2024
Supplementary Figure S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity2024

More from PLoS ONE

Factors influencing elderly people’s intentions to use smartphone mHealth apps: Quantitative researchFri,
Tension reduction from inter-membrane counter-deformation accelerates nuclear electroporationFri,